20.500.12556/DiRROS-31030 Nanotelesa alternativa klasičnim monoklonskim protitelesom Nanobodies an alternative to conventional monoclonal antibodies Težkoverižna protitelesa, prvič odkrita pri kamelidih leta 1989, predstavljajo nekonvencionalno obliko protiteles, sestavljeno izključno iz težkih verig in brez lahkih verig, značilnih za klasična protitelesa. Njihova posamezna variabilna domena, imenovana nanotelo ima ključne prednosti pred konvencionalnimi protitelesi: stabilnost, manjša velikost, visoka topnost v vodi, boljše prehajanje v tkiva in enostavna proizvodnja v rekombinantnih sistemih. Nanotelesa raziskujejo predvsem na področju diagnostike, kjer se uporabljajo v tehnikah, kot so pozitronska emisijska tomografija s hkratno računalniško tomografijo, biosenzorji in imunokromatografski testi. V terapevtske namene jih razvijajo za zdravljenje raka ter infekcijskih in avtoimunskih bolezni. Od prve odobritve kaplacizumaba leta 2018 so bila odobrena še tri zdravila na osnovi nanoteles, kar potrjuje njihov vse večji pomen v translacijski in klinični medicini. heavy-chain antibodies, first discovered in camelids in 1989, represent an unconventional form of antibodies composed solely of heavy chains and lacking the light chains that are characteristic for classical antibodies. Their single variable domain, known as a nanobody offers key advantages over conventional antibodies, such as stability, smaller size, high solubility in water, improved tissue penetration, and easy production in recombinant systems. Nanobodies are primarily explored in the field of diagnostics, where they are used in techniques such as positron emission tomography/computed tomography, biosensors, and immunochromatographic tests. For therapeutic purposes, they are being developed for the treatment of cancer as well as infectious and autoimmune diseases. Since the first approval of caplacizumab in 2018, three additional nanobody-based drugs have been approved, confirming their growing importance in translational and clinical medicine. kaplacizumab monoklonska protitelesa nanotelesa PET/CT rak (medicina) caplacizumab monoclonal antibodies nanobodies cancer PET/CT true false true Slovenski jezik Angleški jezik Neznano 2026-07-10 11:45:44 2026-07-10 11:45:45 2026-07-11 03:51:12 0000-00-00 00:00:00 2026 0 0 Besedilo v slov.; str. 63-73 št. 1 Letn. 77 mar. 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2026-03-01 615 0014-8229 273357059 babic.pdf babic.pdf 1 1732772B055E98E189D0A350D96A1C01 e91761c3adce71a6310fc53323a0a48fb3527470ae815ef215eb29de0034bc5c 20a58142-7c44-11f1-b663-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=47803 Slovensko farmacevtsko društvo 0 0 0